Loading...

PCSA PROCESSA PHARMACEUTICALS INC Other Situations 8-K Filing

PRCS

PCS

PROCESSA PHARMACEUTICALS INC

(PCSA)

2023 8-K

Show Summary

Show Summary

Equity Offerings

Asset Acquisitions

Investor Presentation

Securities Offering

Accounting Firm Change

Clinical Trial Update

Product Pipeline Update

FDA Clearance for Phase 2 C...

Appointment of Chief Financ...

Annual Meeting of Shareholders

Sales Agreement

Presentation at AACR Annual...

Presentation at Investor Co...

Presentation at Conference

Compliance regained with Na...

Securities Purchase Agreement

Phase 1b safety evaluation ...

Expansion of NGC-Cap program

Reverse Stock Split

Presentation at Biotech Sho...

Investor Conferences

Presentation at Conference

Special Meeting Approval

Departure of Directors

Investor Presentation

Presentation at Conference

Appointment of Chief Execut...

Amendment to Increase Autho...

Investor Conferences

Investor Conferences

FDA Guidance for Phase 2 Trial

Presentation at Digestive D...

Earnings Release & Corporat...

Presentation at Healthcare ...

Securities Purchase Agreement

Termination and Suspension

Investor Conferences

External Links:

Processa Pharmaceuticals will be presenting the Phase 2a results of PCS12852, a novel 5-HT4 agonist, at Digestive Disease Week 2023 Annual Meeting.

AI Assistant

PROCESSA PHARMACEUTICALS INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.